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A b s T r A C T
background: recent studies have shown inconsistent results 
about the association between body mass index (bMi) and 
gastrointestinal disorders. The aim of this study was to 
assess the association between bMi and gastrointestinal 
disorders in patients referred for endoscopy.
Methods: Consecutive patients received a questionnaire 
about gastrointestinal symptoms prior to upper gastroin-
testinal endoscopy. The association between bMi and 
gastrointestinal disease and related symptoms was 
determined by adjusted logistic regression analyses.
results: A total of 1023 subjects were included, 303 
(35%) subjects were overweight (bMi 25 to 30 kg/m2), an 
additional 118 (14%) subjects were obese (bMi >30 kg/m2). 
overall, 42% of the patients experienced symptoms of 
gastro-oesophageal reflux disease (gErd), 70% dyspepsia 
and 55% lower abdominal symptoms. in obese patients 
the prevalence of gErd was higher (52%) compared with 
normal weight (44%) and overweight (44%) (ns). reflux 
oesophagitis was found in 13, 17 and 19% for normal 
weight, overweight and obese, hiatus hernia in 7, 9 and 11% 
and barrett’s oesophagus in 6, 7 and 8%, respectively.
Conclusion: More than half the patients undergoing upper 
gastrointestinal (gi) endoscopy were overweight or obese. 
in this patient population, no relation between bMi and gi 
disorders and symptoms was found. however, a small but 
statistically insignificant trend was observed toward obesity 
for patients with gErd-associated symptoms.
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i N T r o d u C T i o N
The prevalence of obesity is increasing worldwide. In the 
past 20 years, the prevalence of obesity has doubled to 12% 
in the Netherlands and has become a major threat to public 
and clinical health.1,2 Obesity is clearly acknowledged as a 
risk factor for several chronic diseases, such as diabetes 
mellitus type 2 and cardiovascular diseases. Moreover, 
obesity has recently been associated with several forms of 
gastrointestinal cancer, such as colon cancer, oesophageal 
adenocarcinoma and gallbladder disease.3-9
A potential role of obesity in gastrointestinal symptoms 
is unclear. Reports from several health surveys show 
inconsistent results. Most recent studies show a relationship 
between obesity and the occurrence of gastrointestinal 
symptoms, especially of heartburn and regurgitation.10-16 
This relation might be explained by the fact that obese 
persons experience a higher intra-abdominal pressure, 
slower oesophageal transit and decreased acid clearance 
from the oesophagus due to hiatus hernia than persons 
with a normal body mass index (BMI).17-19 Consequently, 
hiatus hernia can cause GERD symptoms. Additionally, 
data from two large studies show that dyspeptic symptoms 
decline if overweight patients lose weight.20,21 
Besides upper gastrointestinal symptoms, data are also 
scarce on a possible relation between obesity and upper 
gastrointestinal pathology.22 The patient population 
referred for upper gastrointestinal endoscopy is prone to 
organic diseases due to long-term persistent symptoms not 
reacting to acid inhibitors. The results of the present study, 
in a patient population referred for upper gastrointestinal 
endoscopy, could reveal new insights into the relation 
between patients BMI and gastrointestinal symptoms and 
disease. The outcome may help in differentiating between 
gastrointestinal diseases based on body mass index and 
gastrointestinal symptoms.
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M E T h o d s
subjects
A total of 1103 consecutive patients consented to participate 
in this study. They were all referred to two experienced 
gastroenterologists at the Canisius Wilhelmina Municipal 
Hospital, Nijmegen, the Netherlands, by general 
practitioners or specialists for diagnostic upper gastroin-
testinal endoscopy between March 2002 and March 2004. 
All included patients were 18 years or older. 
Two weeks prior to endoscopy, the patients received a 
questionnaire that included demographic information, 
body weight and height, history of smoking, amount of 
alcohol and coffee intake, medical history and present 
use of medication. We excluded patients with a history 
of gastrointestinal disease, such as cancer, inflammatory 
bowel disease, celiac disease and gastrointestinal 
resections. Patients who did not complete the questionnaire 
were excluded as well.
definitions
BMI was calculated as body weight (kg) divided by the 
square of height (m) and categorised according to the World 
Health Organisation (WHO) classification of overweight 
and obesity: normal weight BMI <25 kg/m2, overweight 
BMI 25 to 30 kg/m2, obesity BMI ≥30 kg/m2.1 Acid 
inhibitors were defined as antacids, H2-receptor antagonists 
and proton pump inhibitors. Coffee and alcohol intake were 
divided into user or non-user and smoking into current 
smoker or non-smoker/ex-smoker.
Patients were asked to score gastrointestinal symptoms 
over the past four weeks by a validated gastrointestinal 
symptom rating scale (GSRS).23 This included specific 
questions about the type of symptoms and severity on a 
seven-point Likert scale. Symptoms were categorised into 
three groups: ‘GERD’ (gastro-oesophageal reflux disease), 
‘dyspepsia’ and ‘lower abdominal’. ‘GERD’ was defined as 
heartburn and regurgitation. Epigastric pain, abdominal 
bloating and nausea were categorised as ‘dyspepsia’. ‘Lower 
abdominal’ comprised pain in the lower abdomen (general, 
after a meal, when hungry, after defecation, diarrhoea and 
constipation). Severity of gastrointestinal symptoms was 
described as no symptoms, mild, moderate, quite a lot, 
severe, very severe and unbearable symptoms. None and 
mild symptoms were combined as ‘no symptoms’ and 
compared with the others. 
All gastric and duodenal diagnosis found at endoscopy 
were confirmed by pathology reports. Barrett’s oesophagus 
was defined by endoscopic ‘Barrett’s oesophagus’ or 
‘metaplasia’ in the pathology report. In this way, gastritis 
and duodenitis diagnosed by endoscopy were confirmed 
by pathology reports. Also, endoscopic ‘suspicious for 
oesophagus or gastric malignancies’ were confirmed to 
pathologically proven malignancies. Active Helicobacter 
pylori infection was proven by histological investigations 
of antral biopsy specimens.
statistical analysis
Primary analysis investigated the association between BMI 
and the prevalence of gastrointestinal symptoms. In addition, 
we assessed whether overweight and obese patients differ 
in gastrointestinal pathology compared with the group with 
normal weight. For this purpose, we initially studied the three 
BMI groups for basic demographics and use of nonsteriodal 
anti-inflammatory drugs (NSAIDs) or acid inhibitors. 
Also the frequencies of the (categorised) gastrointestinal 
symptoms in the study population were assessed. The 
relations between BMI and both gastrointestinal symptoms 
and diseases were analysed using Pearson χ2 test. The 
evaluation of BMI as a risk factor for gastrointestinal 
symptoms and disease was determined by adjusted 
logistic regression. Factors used for adjustment (age, 
gender, Helicobacter pylori infection, alcohol and coffee 
consumption, current smoking and use of NSAIDs or acid 
suppressive medication) were made explicit by literature. 
An additional analysis was performed to assess whether 
BMI influences the relation between hiatus hernia and 
GERD symptoms. Analyses were performed using SAS 
statistical software, version 8.0.
results
A total of 1103 patients were included in this study. We 
excluded four patients because they were younger than 
18 years, 33 patients who had a history of gastrointestinal 
cancer, 14 patients with a history of chronic gastroin-
testinal disease and 29 patients with a gastrointestinal 
resection in the past. In total, 1023 patients were eligible 
for analysis in this study, 49% were male and the mean 
age of the population was 55.4 years (SD 15.4). Mean BMI 
was 25.5 (SD 4.5) kg/m2. Half of the patient population 
was overweight (35%) or obese (14%) (table 1). Statistically 
significantly more women were obese (p<0.01). In the study 
population, prevalence of acid suppressive medication was 
high as expected (total of 5.5% were taking H2-receptor 
antagonists, and 47.6% were on proton pump inhibitors), 
but not different between normal weight (53%), overweight 
(58%) and obese (51%) patients (p=0.50). 
In the previous four weeks, GERD symptoms were reported 
by 45%, dyspepsia by 67% and lower abdominal symptoms 
by 59% of the total study population. These percentages 
did not differ significantly between the three BMI groups 
(table 2). Half of the patients in the obese group (52%) 
experienced a GERD symptom in the four weeks prior 
to upper gastrointestinal endoscopy compared with 44% 
in both normal and overweight groups. This finding was 
largely contributable to heartburn, but even this difference 
was not found to be statistically significant.
46
2
f e b r u a r y  2 0 0 6 ,  V o l .  6 4 ,  N o .  2
Van Oijen, et al. Obesity and gastrointestinal disorders.
Table 1. Demographics and body mass index
demographics (%) body mass index (kg/m2) p value
<25 (n=437) 25-30 (n=303) ≥30 (n=118)
Mean age (SD) 53.5 (16) 57.5 (15) 54.4 (14) 0.78
Older than 50 268 (61%) 218 (72%) 79 (67%) <0.05
Male gender 209 (48%) 171 (56%) 44 (37%) <0.01
Western European origin 356 (91%) 267 (95%) 97 (91%) 0.09
Current alcohol users 221 (51%) 199 (66%) 56 (48%) <0.01
Coffee users 372 (86%) 268 (90%) 100 (87%) 0.27
Current smoker 157 (36%) 77 (25%) 30 (25%) <0.01
NSAID use 7 (3%) 3 (2%) 5 (7%) 0.12
Antacids 2 (1%) 2 (1%) 0 (0.0%) 0.67
H2-receptor antagonists 17 (6%) 9 (5%) 4 (5%) 0.79
Proton pump inhibitors 120 (46%) 85 (51%) 35 (46%) 0.89
Table 2. Gastrointestinal symptoms and body mass index
symptoms (%) body mass index (kg/m2) p value*
<25 25-30 ≥30
GERD 194 (44%) 134 (44%) 61 (52%) 0.33
Heartburn 138 (33%) 101 (35%) 51 (44%) 0.07
Regurgitation 157 (38 %) 116 (41%) 49 (44%) 0.49
Dyspepsia 299 (68%) 198 (65%) 83 (70%) 0.54
Lower abdominal 268 (61%) 173 (57%) 67 (57%) 0.44
*Adjusted for gender, age, origin, smoking, use of alcohol, coffee, gastric acid suppressive medication and NsAids, infection with helicobacter 
pylori. gErd = gastro-oesophageal reflux disease.
Table 3. Body mass index and gastrointestinal disease
gastrointestinal disease body mass index (kg/m2) p value*
<25 25-30 ≥30
Normal 219 (50%) 148 (49%) 57 (48%) 0.91
Oesophagitis 56 (13%) 50 (17%) 23 (19%) 0.13
Gastritis 85 (20% 44 (15%) 24 (21%) 0.16
Duodenitis 23 (5%) 12 (4%) 5 (4%) 0.68
Peptic ulcer 18 (4%) 10 (3%) 6 (5%) 0.68
Hiatus hernia 29 (7%) 27 (9%) 13 (11%) 0.24
Barrett’s oesophagus 27 (6%) 20 (7%) 10 (8%) 0.67
Oesophagus carcinoma 3 (1%) 0 (0%) 0 (0%) 0.23
Gastric carcinoma 0 (0%) 1 (0.3%) 0 (0%) 0.40
Helicobacter pylori infection 60 (14%) 34 (11%) 17 (14%) 0.53
*Adjusted for gender, age, origin, smoking, use of alcohol, coffee, acid inhibitors and NsAids, infection with helicobacter pylori.
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Table 4. Association between hiatus hernia and GERD symptoms
bMi* hiatus hernia gErd (%) p value
Normal (<25 kg/m2) Yes 18 (62.1%) 0.05
No 174 (43.1%)
Overweight (25-30 kg/m2) Yes 17 (63.0%) 0.04
No 116 (42.2%)
Obese (≥30 kg/m2) Yes 7 (53.9%) 0.84
No 53 (51.0%)
*Trend over bMi subgroups, p=0.55. gErd = gastro-oesophageal reflux disease.
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In approximately half of the population, endoscopy did 
not reveal any abnormalities (table 3). Regarding gastroin-
testinal pathology, no differences were found between the 
three BMI groups. A small but insignificant trend could be 
observed for oesophageal diseases. For the normal weight, 
overweight and obese patients we found oesophagitis in 
13, 17 and 19%, hiatus hernia in 7, 9 and 11% and Barrett’s 
oesophagus in 6, 7 and 8%, respectively.
Table 4 describes the association between hiatus hernia 
and GERD symptoms, subdivided for the BMI classes. 
The normal and overweight patients with hiatus hernia 
are more prone to GERD symptoms, in obese patients this 
association was not present. 
d i s C u s s i o N
We studied the association between BMI and prevalence 
of gastrointestinal symptoms and upper gastrointestinal 
abnormalities in patients referred for endoscopy. Half 
of our population was overweight or obese and again 
in half endoscopy did not reveal any abnormalities. 
With an increase in BMI, there was a small but not 
statistically significant increase in prevalence of diseases 
and symptoms related to the oesophagus.
Obesity is becoming more and more prevalent. Obese 
patients are not only at risk for cardiovascular diseases and 
diabetes mellitus, but also have a decreased health-related 
quality of life.24,25 Medical consumption of this specific 
population is higher and in the near future the health 
system will need investments to cover this.
The association between BMI and upper gastrointestinal 
diseases has been studied before. The population-based 
study by Locke et al. aimed at assessing risk factors for 
reflux oesophagitis.12 Patients defined as obese conform the 
WHO guidelines (>30 kg/m2) had a three times higher risk 
of oesophagitis (OR 2.8, 95% CI 1.7 to 4.5). In our study we 
did find a small trend for the association between obesity 
and oesophagitis, but not as firm as Locke and colleagues. 
We did, however, find not only reflux oesophagitis but also 
other oesophagus-related diseases (Barrett’s oesophagus and 
hiatus hernia) to be slightly more prevalent in the higher 
BMI classes. A recent study by El-Serag et al. also showed 
more frequent hiatus hernia and reflux oesophagitis among 
the overweight and obese.10 They suggested that obesity 
could be the cause of hiatus hernia, which could be followed 
by GERD and reflux oesophagitis. Hiatus hernia was also 
related to GERD symptoms in our study, but not in the obese 
patients, which implicates involvement of other factors than 
body mass index for the occurrence of hiatus hernia. 
The literature is inconsistent about the association between 
BMI and gastrointestinal symptoms. This inconsistency 
could be explained by several factors: the choices for 
certain cut-offs, the study population and the absence of 
the association. Study protocols found in literature used 
different cut-off points for BMI, some were based on 
statistical reasons (e.g. quartiles), others adopted cut-offs 
from other publications. For better comparison we used 
the most common definition, described by the WHO.1 In 
contrast to our study the association was previously studied 
in the general population and in outpatients, whereas 
we studied patients referred for upper gastrointestinal 
endoscopy, which is a population with a higher occurrence 
of upper gastrointestinal diseases and related symptoms. 
Moreover, in our population both symptoms and diagnosis 
could be studied.
The large community-based randomised controlled trial 
by Murray et al. in the United Kingdom showed a positive 
correlation between BMI and prevalence of gastrointestinal 
symptoms.11 In their study, 21% of the patients were obese 
and 41% overweight according to WHO guidelines, which 
is quite similar to our results with 14 and 35% obese and 
overweight patients, respectively. Their results showed 
adjusted odds ratios for frequency of symptoms occurring 
at least once a week in overweight patients compared 
with those of normal weight of 1.8 (95% CI 1.33-2.50) for 
heartburn and 1.5 (95% CI 1.13-1.99) for regurgitation. 
Corresponding odds ratios relating to obese patients 
were 2.9 (95% CI 2.07 to 4.08) and 2.2 (95% CI 1.44 to 
3.45), respectively. This British study was conducted in 
the general population, while we studied the association 
between BMI and GERD symptoms in a population 
referred for upper gastrointestinal endoscopy.
All studies have their limitations. In our study, body weight 
and height were obtained on a self-report form, rather than 
measured by a physician. Especially obese patients are more 
likely to underreport their body weight, which may have lead 
to an underestimation of our obese population. It is unclear 
whether underreporting of body weight plays an important 
role in gastrointestinal patients. These patients may be well 
aware of their body weight, as it is usually measured during 
their visits to the gastroenterologist. Moreover, the majority 
of our study population were taking or had been taking acid 
suppressive medication, which might contribute to the lower 
prevalence of peptic ulcer disease and reflux oesophagitis, 
compared with other study results handling the relation 
between BMI and reflux oesophagitis. However, our patient 
population was a better reflection of common practice, 
where many patients had already experienced pretreatment 
with any acid suppressive medicament.
The observational setting of this study introduces physician 
behaviour as confounding. All patients in our study were 
referred by their general practitioner. Patients with a 
higher BMI can be referred to secondary care at an 
earlier stage than others, because of the referring doctor’s 
knowledge of the current literature. This confounding-by-
indication could have interfered with our results, but more 
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importantly, it introduces a poor comparison with other 
(endoscopic) study results. 
In conclusion, more than half of the patients undergoing 
endoscopy were overweight or obese. In this patient 
population, no relation between BMI and GI disorders and 
symptoms was found, although a small but statistically 
insignificant trend was observed toward obesity for patients 
with GERD associated symptoms.
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